Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbavance versus best available therapy for serious carbapenem-resistant Enterobacteriaceae infections
2014-000546-30Phase 3Completed
- Sponsor
- Rempex Pharmaceuticals, Inc.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meropenem + vaborbactam in Enterobacteriaceae infection, complicated urinary tract infection (cUTI), acute pyelonephritis and 1 more (2 arms), sponsored by Rempex Pharmaceuticals, Inc. Started Oct 2014; status: completed.
02
Drugs
meropenem + vaborbactam
03
Conditions
Enterobacteriaceae infectioncomplicated urinary tract infection (cUTI)acute pyelonephritisBacteremia
Beyond the preview
Go deeper on 2014-000546-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000546-30.